Status:
COMPLETED
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
Lead Sponsor:
XOMA (US) LLC
Conditions:
Osteoarthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of inflammatory erosive osteoarthritis of the hand.
Eligibility Criteria
Inclusion
- Diagnosis of hand osteoarthritis
- Joint tenderness and/or redness
- At least one erosion by X-ray (as determined by the central reader)
- Contraceptive measures adequate to prevent pregnancy during the study
Exclusion
- History of inflammatory disease other than hand EOA including: secondary post-traumatic OA; rheumatoid arthritis; spondylarthropathies; erosion of the ulnar styloid process; psoriatic arthritis; skin psoriasis; erosions of the wrist; fibromyalgia
- History of gout, pseudogout, or hemochromatosis
- History of allergic or anaphylactic reactions to monoclonal antibodies
- History of recurrent or chronic systemic infections
- Known allergy to acetaminophen
- Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT01882491
Start Date
May 1 2013
End Date
February 1 2014
Last Update
March 4 2014
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville, Alabama, United States
2
Tucson, Arizona, United States
3
Roseville, California, United States
4
Sacramento, California, United States